We compiled last week’s warning letters for you. Take a look.
Last week, the FDA issued a warning letter after a study drug was administered even though the study had been placed on clinical hold.
From poor water quality to a hush-up of failing test results, we cover five warning letters the FDA sent to companies this week.
This week the FDA posted 4 new warning letters. One was issued to a cell/tissue product manufacturer, 1 to a firm for failure to list, 1 to a compounding pharmacy, and 1 to a device manufacturer. We cover 3 of these in this post.
This was an exceptionally light week of only 2 published warning letters, 1 of which was a compounding pharmacy which we cover in this post.